Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

HAT Platform

  HUMAN AFRICAN TRYPANOSOMIASIS
HAT PLATFORM


Founded: 2005 in Kinshasa, Democratic Republic of the Congo
Members: National Control Programmes of most affected endemic countries: Angola, Central African Republic, Chad, Democratic Republic of the Congo, Republic of Congo, South Sudan, Sudan, Uganda; Swiss Tropical and Public Health Institute (Swiss TPH), Switzerland; Institute of Tropical Medicine in Antwerp (ITMA), Belgium; Institut National de Recherche Biomédicale (INRB), DRC; Kenya Agricultural Research Institute – Trypanosomiasis Research Centre (KARI-TRC), Kenya; Tropcial Medicine Research Institute (TMRI), Sudan; MSF/Epicentre; Institut Pasteur Bangui, CAR; Foundation for Innovative New Diagnostics (FIND); WHO-TDR; Regional networks such as Eastern Africa Network for Trypanosomosis (EANETT), Centre interdisciplinaire de Bioéthique pour l'Afrique Francophone (CIBAF); Special Programme for Research and Training in Tropical Diseases (WHO-TDR) as observer

Funding: Department for International Development (DFID), UK; Federal Ministry of Education and Research (BMBF through KfW), Germany; French Development Agency (AFD), France; Médecins Sans Frontières/Doctors without Borders, International; Medicor Foundation, Liechtenstein; Ministry of Foreign Affairs (DGIS), The Netherlands; Ministry of Foreign and European Affairs (MAEE), France; Spanish Agency for International Development Cooperation (AECID), Spain; Specific International, Scientific Cooperation Activities (FP5) European Union; Swiss Agency for Development and Cooperation (SDC), Switzerland

Objectives: To build and strengthen treatment methodologies and clinical trial capacity in HAT-endemic countries, so that new treatments for this fatal disease can be rapidly and effectively evaluated, registered, and made available to patients. After the success of the Nifurtimox-Eflornithine Combination Therapy (NECT), included in the WHO List of Essential Medicines for the treatment of stage 2 HAT, the primary goals of the HAT Platform are to develop appropriate clinical trial methodologies for HAT, overcome system challenges related to administrative and regulatory requirements, strengthen clinical trial capacity (human resources, infrastructure, equipment), and share information and strengthen ties among endemic countries.
 

 

HAT Platform Brochure


In the Media


[17 September, 2014]
Radio Okapi
"Dr Augustin Kadima Ebeja : 'La RDC est le pays le plus endémique de la maladie du sommeil'"
Dr Augustin Kadima Ebeja en ‘Invité du Jour’ sur Radio Okapi (interview audio)
Click here to read the article

[17 September, 2014]
Radio Okapi
"Les moyens manquent"
Interview de Dr Augustin Kadima Ebeja
Click here to read the article



HAT Platform Newsletters



DNDi Newsletters

 

Tags: HAT – Sleeping Sickness
Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License